Breaking News, Financial News

Financial Report: Wyeth

Wyeth

2Q Revenues: $5.2 billion (+9%)

2Q Earnings: $1 billion (+9%)

YTD Revenues: $10 billion (+8%)

YTD Earnings: $2.2 billion (+6%)

Comments: Pharmaceuticals revenue growth of 11% for quarter was driven by Enbrel and Prevnar. Enbrel sales (outside the U.S. and Canada) were $370 million, up 36% and Prevnar sales were $518 million, an increase of 60%. The company submitted two NDAs in the quarter, for bazedoxifene (osteoporosis) and desvenlafaxine succinate (vasomotor symptoms). Also, Tygacil was approved in Europe.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters